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Abstract
Carbapenem-resistant Klebsiella pneumoniae (CR-KP) is becoming a common cause of healthcare-associated infection in Italy, with high
morbidity and mortality. Prevalent CR-KP clones and resistance mechanisms vary between regions and over time. Therapeutic approaches
and their impact on mortality have to be investigated. We performed a prospective study of patients with CR-KP isolation, hospitalized in
nine hospitals of Rome, Italy, from December 2010 to May 2011, to describe the molecular epidemiology, antibiotic treatment and risk
factors for mortality. Overall, 97 patients (60% male, median age 69 years) were enrolled. Strains producing blaKPC-3 were identiﬁed in 89
patients, blaVIM in three patients and blaCTX-M-15 plus porin defects in the remaining ﬁve patients. Inter-hospital spread of two major
clones, ST512 and ST258, was found. Overall, 36.1% and 20.4% of strains were also resistant to colistin and tigecycline, respectively.
Infection was diagnosed in 91 patients who received appropriate antibiotic treatment, combination therapy and removal of the infectious
source in 73.6%, 59.3% and 28.5% of cases, respectively. Overall, 23 different antibiotic regimens were prescribed. In-hospital mortality was
25.8%. Multivariate analysis adjusted for appropriate treatment, combination therapy and infectious-source removal, showed that Charlson
comorbidity score, intensive-care unit onset of infection, bacteraemia and infection due to a colistin-resistant CR-KP strain were
independent risk factors for mortality. The spread of clones producing K. pneumoniae carbapenemases, mainly ST258, is currently the major
cause of CR-KP infection in central Italy. We observed a high rate of resistance to colistin that is independently associated with worse
outcome.
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Introduction
Carbapenem resistance represents the current challenge in the
treatment of infections caused by Gram-negative bacteria [1].
In Italy, since the ﬁrst detections of resistance to carbapenems
in Acinetobacter baumannii and Pseudomonas aeruginosa during
the late 1990s [2,3], concern has risen for the detection of
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carbapenem-resistant Enterobacteriaceae, especially Klebsiella
pneumoniae [4–7].
Carbapenem resistance can be the result of various
mechanisms including the production of a carbapenemase
enzyme, such as metallo-b-lactamases, K. pneumoniae carba-
penemases (KPCs), and OXA-48; and the combination of
porins defect plus extended spectrum b-lactamase (ESBL) or
AmpC enzyme production [8]. Strains producing carbapene-
mases are more resistant to carbapenems compared with
those with other mechanisms of resistance, and their genes
may be achieved horizontally, allowing them to spread widely.
In Italy, carbapenem-resistant K. pneumoniae (CR-KP) strains
showing the combination of porins defect plus ESBL produc-
tion were becoming common in some centres [9], whereas in
others carbapenemase-producing strains were prevalent and,
in most cases, they were clonally related [10].
The therapeutic armamentarium against infection by CR-KP
is limited to antibiotics with high potential toxicity, such as
colistin and gentamicin, or with a poor pharmacokinetic/
pharmacodynamic proﬁle, as tigecycline. The use of these
antibiotics has been associated with the emergence of
resistance against them [11]. For these reasons, most authors
recommend using combination therapy with different classes
of antibiotics to improve the efﬁcacy and to prevent the
emergence of further resistance [12]. However, the evidence
about which combination is optimal is far from clear, and the
impact of resistance to the last antimicrobial choices available
in clinical practice is unknown.
We performed a prospective multicentre study in nine
hospitals in Rome, Italy, to assess which are the current
prevalent clones and mechanisms of resistance among CR-KP
isolates, to describe the characteristics of patients colonized
or infected by such strains, and to analyse the therapeutic
management of patients with CR-KP infection and the
predictors of mortality in these patients.
Methods
Study design and setting
We performed a multicentre prospective observational study
based on an alert system provided by nine microbiology
laboratories belonging to the SEERBIO-GRAB network. These
laboratories serve a population of c. 2.5 million people in
Rome, and analyse clinical samples collected in one teaching
institution, six tertiary hospitals, one clinical and research
institute, and one long-term care facility, with a total of 4000
beds, ranging from 100 to 1200 beds per centre.
During December 2010 through to May 2011, the clinical
and microbiological data of all consecutive patients with
isolation of a K. pneumoniae strain showing reduced suscepti-
bility to ertapenem (MIC  1 mg/L), from different specimens,
were collected. An investigator contacted the participating
centres to monitor the inclusion of all eligible cases. The
completeness and consistency of the protocols were system-
atically reviewed before data were entered into the database.
Diagnostic and therapeutic management for all patients,
including the need to obtain surveillance cultures, was not
standardized and decisions were made at the discretion of the
attending physician.
The study involved the analysis of existing clinical and
laboratory data that were anonymous (an alphanumeric code,
composed of a letter identifying the hospital of origin and the
number indicating the clinical history, was assigned to each
patient) before being entered in the database. Hence, accord-
ing to local and national regulations, this analysis was exempt
from formal approval by the Ethics Committee.
Clinical data and deﬁnitions
The medical charts of the patients were reviewed according to
a pre-established protocol including the following variables:
age, sex, diabetes, chronic obstructive pulmonary disease,
renal insufﬁciency (with or without dialysis), liver cirrhosis,
active cancer, human immunodeﬁciency virus infection, solid
organ transplantation, haematological disease with or without
stem cell transplantation, and corticosteroid therapy
( 10 mg/day of prednisone during  15 days).
Data on prior healthcare exposure included: admission
from other hospital or long-term care facility, previous
hospitalization in the past 12 months, prior admission to
intensive-care unit (ICU) or major surgery in the past 30 days,
and receipt of any antibiotic during  48 h in the past 30 days.
Dates of hospital admission and of CR-KP isolation, ward of
stay, and presence of devices including central venous catheter
(CVC), mechanical ventilation and urinary catheter at the time
of CR-KP isolation were recorded.
Infection was established according to standard deﬁnitions
[13], the probable infectious source was determined on the
basis of the microbiological results and physician’s judgment.
Bloodstream infections (BSI) were deﬁned as low-risk BSI if the
portal of entry was the CVC or urinary tract, and as high-risk
BSI in the other cases [14].
Data on therapeutic management included: type, dosage,
route of administration and dates of start and of end for any
antibiotic. Appropriate antimicrobial therapy was deﬁned as
treatmentwith at least one in vitro active antibiotic for aminimum
of 48 h [15]. Removal of the infectious sourcewas also recorded.
Outcome was evaluated using the following: development of
septic shock; in-hospital death; and length of hospitalization
from the CR-KP isolation.
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Strain identiﬁcation and antimicrobial susceptibility test
Isolates were studied at the participating centres and sent to
two reference laboratories (Istituto Superiore di Sanita` and
San Filippo Neri).
Klebsiella pneumoniae identiﬁcation and antimicrobial suscepti-
bility were determined by individual laboratories using the Vitek2
system, AST-N089 card (bioMe´rieux, Marcy l’Etoile, France).
Ertapenem-resistant strains (MIC >1 mg/L) were sent to
Istituto Superiore di Sanita`, Rome, for conﬁrmation and
molecular screening of resistance mechanisms. All strains were
tested for carbapenemase production by modiﬁed Hodge test
[16]. The carbapenemase-positive strains were tested by
combined-disc method using a disc of meropenem (10 lg)
with or without 400 lg phenylboronic acid or 10 lL 0.1 M
EDTA on Mueller–Hinton agar II [17].
Antibiotic susceptibilities to carbapenems, colistin, tigecy-
cline, aminoglycosides and fosfomycin were conﬁrmed by the
San Filippo Neri laboratory using the microdilution method.
Breakpoints were interpreted in accordance with the European
Committee on Antimicrobial Susceptibility Testing guidelines.
b-Lactamase gene detection and characterization of porin
genes
All the ertapenem-resistant/Hodge test-positive strains were
tested by PCR ampliﬁcation and DNA sequencing for the
presence of the blaKPC, blaVIM, blaNDM, blaOXA-48, blaCTX-M and
blaCMY genes, using methodology and primers that were
described previously [18–20]. Full-length sequences were
obtained for the blaCTX-M, ompK35 and ompK36 genes in the
ertapenem-resistant/Hodge test-negative strains, using previ-
ously described methodology and primers [21].
Strain genotyping
The gapA and tonB genes, chosen as the most discriminatory
alleles of the multilocus sequence typing were initially ampliﬁed
and sequenced to categorize the strains in four major groups:
ST258-like (gapA allele 3, tonB allele 79), ST512-like (gapA allele
54, tonB allele 79), ST37-like (gapA allele 2, tonB allele 16) and
other sequence types (other-STs), respectively. Fifty-ﬁve
selected strains (16 ST258-like, 20 ST512-like, four ST-37 and
eight strains showing other-STs) were fully typed by multilocus
sequence typing performedon the rpoB, gapA,mdh, pgi, phoE, infB
and tonB genes, as previously described [22]. Sequence types
were assigned at the http://www.pasteur.fr/recherche/geno
pole/PF8/mlst/ website. Plasmid typing was performed by PCR-
based replicon typing as previously described [23,24].
Statistical analysis
Categorical variables are presented as absolute numbers and
their relative frequencies. Quantitative variables are presented
as mean and standard deviation (SD) if normally distributed or
as median and interquartile range (IQR) if non-normally
distributed. We compared categorical variables between two
groups (survivors and non-survivors) using the Pearson chi-
square and Fisher exact tests, while the parametric Student’s t
or non-parametric Mann–Whitney U tests were used to
compare quantitative variables, depending on their distribu-
tion. A binary logistic regression model was used in the
multivariate analysis to analyse risk factors for in-hospital
mortality. Variables with p <0.1 in the univariate analysis were
included in the multivariate models. Differences were consid-
ered to be signiﬁcant for p <0.05. The analysis was carried out
using SPSS 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Microbiology characteristics
During the study period, 97 patients with isolation of a CR-KP
strain from one or more samples including: urine (34), blood
(34), lower respiratory tract (13), surgical wound (8), intra-
abdominal ﬂuid (7), CVC tips (12), rectal swab (3) and
cerebrospinal ﬂuid (1) were identiﬁed (Fig. A1 in Appendix 2).
The rate of antimicrobial resistance was 95.9%, 89.8%,
79.6%, 36.1% and 20.4% for imipenem, meropenem, gentami-
cin, colistin and tigecycline, respectively. Susceptibility testing
to fosfomycin was performed for 24 strains, 12 (50%) of them
were found to be resistant. The overall distribution of the
colistin MIC values is shown in Table A1 (in Appendix 2).
The following mechanisms of carbapenem resistance were
identiﬁed: production of KPC-3 in 89 cases; production of
VIM-1 in three cases (all from the same hospital); and
production of CTX-M-15 plus porin defects in the remaining
ﬁve patients. The modiﬁed Hodge test was positive for all
strains producing carbapenemases, but was negative for those
producing ESBLs associated with porin defect.
Among strains producing KPC-3, two major clones were
identiﬁed by multilocus sequence typing: ST512 and ST258,
belonging to the same clonal complex (CC-258). KPC-3 was
also identiﬁed in clones ST646 (new ST), ST650 (new ST),
ST14 and ST101 (Table 1). The blaVIM-1 gene was identiﬁed in
clones ST646, ST647 and ST648 (three new STs). Among
strains producing ESBL combined with outer membrane
protein (OmpK) defects, three belonged to ST37, and the
other was assigned to the new ST649 (Table 1).
The blaKPC-3 genewas locatedonplasmids carrying the FIIk and
FIBk replicons.The samerepliconcontentwasobserved in strains
ST512, ST258, ST650, ST14 and ST101. The ST258 clones
identiﬁed in 14 strains from twohospitals harboured an additional
IncA/C plasmid, carrying the CMY-2 AmpC b-lactamase.
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Clinical characteristics
The clinical characteristics of the patients are summarized in
Table 2.
The median age was 69 years (IQR 50–77). Most patients
had previous healthcare exposure, and had received antibiotics
in the last 30 days. At the time of CR-KP isolation, patients
were hospitalized in ICU, medical and surgical wards in 47.4%,
38.1% and 14.4% of cases, respectively.
Infection was diagnosed in 91 patients and colonization was
established in the remaining six patients (Table 2).
The 35 CR-KP strains that were resistant to colistin caused
infection in 32 patients (including twelve with BSI; nine with
uncomplicated urinary infection; ﬁve with lower respiratory
tract infection; ﬁve with surgical site infection; and one with an
intra-abdominal infection) and were deemed as colonizing in
the remaining three cases.
The overall in-hospital mortality among CR-KP-infected
patients was 25.8%. The mortality rates among patients
infected by colistin-susceptible and colistin-resistant CR-KP
were 20.3% and 40.6% (p 0.04), respectively.
Therapeutic management
The antimicrobial treatment was deemed appropriate in 73.6%
of patients with CR-KP infection. Monotherapy and combina-
tion therapy, with two or more classes of antibiotics, were
administered in 40.7% and 59.3% of cases, respectively. The
antibiotics used were: colistin, 29.6%; tigecycline, 24.6%;
aminoglycosides, 21.6%; fosfomycin, 13.5%; piperacillin-tazo-
bactam, 4.3%; carbapenems, 3%; and third-generation cepha-
losporins, 3%.
Overall, 23 different regimens were prescribed, the most
common were: monotherapy with gentamicin, 17.6%;
combination therapy with colistin plus tigecycline, 17.6%;
monotherapy with colistin, 11%; and combination therapy
with tigecycline plus fosfomycin, 6.6%. Ten patients (11%)
received combination therapy with three different classes of
antibiotics.
TABLE 1. Molecular typing results and b-lactamases genes in Klebsiella pneumoniae analysed in this study
No. strains Hospitals CARB. gene CTX CMY PBRT MLST
71 A, B, C, D, E, F blaKPC-3 neg neg FIIk, FIBk ST512, ST258 (CC-258)
14 B, G blaKPC-3 neg blaCMY-2 FIIk, FIBk, A/C ST258
1 B blaKPC-3 neg neg FIIk, FIBk ST650
1 H blaKPC-3 neg neg FIIk, FIBk ST14
1 E blaKPC-3 neg neg FIIk, FIBk ST101
1 E blaKPC-3 neg neg FIIk, N ST646
1 E blaVIM-1 neg neg FIIk, N ST646
1 E blaVIM-1 neg neg FIIk, A/C ST648
1 E blaVIM-1 neg neg FIIk ST647
4 A, B neg blaCTX-M-15 neg FIIk, FII ST37
1 I neg blaCTX-M-15 neg FIIk, FII ST649
CARB, carbapenemase; PBRT, PCR-based replicon typing [20]; MLST, multi-locus sequence typing [22].
TABLE 2. Characteristics of patients colonized or infected
by carbapenem-resistant Klebsiella pneumoniae (CR-KP)
(n = 97), n (%)
Demographic data
Age (years, median, IQR) 69, 50–77




Chronic obstructive pulmonary disease 33 (34)
Chronic kidney disease 28 (28.9)
Cancer 20 (20.6)
Chronic liver disease 6 (6.2)
Charlson comorbidity score (median, IQR) 5, 3–8
Prior healthcare exposure
Hospitalization in the past 1 year 89 (91.8)
Admission to intensive-care unit
in the past 1 month
74 (76.3)
Surgery in the past 1 month 68 (70)
Antibiotic exposure in the past 30 days
Any 95 (97.9)










Ward, length of stay and devices at the
time of CR-KP isolation
Intensive-care unit 46 (47.4)
Medical 37 (38.1)
Surgical 14 (14.4)
Days of hospitalization before CR-KP
isolation (median, IQR)
15, 8–32
Urinary catheter 90 (92.8)
Central venous catheter 67 (69)
Mechanical ventilation 46 (47.4)
APACHE II score (median, IQR)b 15, 12–20
Clinical syndrome
Colonization 6 (6.2)
Urinary tract infection 29 (29.9)
Bloodstream infection (BSI) 34 (35.1)
Low risk BSI 16 (16.5)
High risk BSI 18 (18.6)
Lower respiratory tract infection 14 (14.4)
Skin and soft tissues infectionc 11 (11.3)
Intra-abdominal infection 3 (3.1)
Outcome
Septic shock 15 (15.2)
In-hospital death 25 (25.8)
Length of hospital stayd (days, median, IQR) 20, 12–33
IQR, interquartile range; ICU, intensive care unit.
aImmunosuppression includes patients with solid organ transplantation, cortico-
steroid therapy, and human immunodeﬁciency virus infection.
bAPACHE II score at the ICU admission was calculated for the 46 patients
hospitalized in ICU at the time of CR-KP isolation.
cSkin and soft tissues infection includes surgical site infections.
dLength of hospital stay was computed since the isolation of CR-KP.
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Overall, 48 patients received colistin for CR-KP infection,
11 of them as monotherapy and 37 in combination with other
agents. The relationship between colistin MIC values and
mortality for both groups was analysed (Table A2 in Appen-
dix 2). Patients with isolates showing lower colistin MIC values
had better outcomes.
Fourteen of the 16 patients treated with gentamicin
monotherapy had uncomplicated urinary infection; the other
two presented with bacteraemia from urinary source and one
of them died on septic shock during treatment.
Removal of the infectious source was performed in 26
patients, in 14 by surgical drainage, and in 12 (all with CVC-
related BSI) by removal of the CVC.
Risk factors for in-hospital mortality
Univariate analysis of the factors associated with in-hospital
mortality is shown in Table 3. Multivariate analysis adjusted for
appropriate antibiotic treatment, combination therapy, and
removal of the infectious source, showed that the Charlson
comorbidity score (OR 1.42, 95% CI 1.15–1.76, p 0.001); ICU
onset of the CR-KP infection (OR 18.05, 95% CI 3.90–83.51,
p <0.001); BSI (OR 4.92, 95% CI 1.35–17.28, p 0.01); and
infection caused by a colistin-resistant strain (OR 4.15, 95% CI
1.17–14.74, p 0.02) were the independent risk factors for in-
hospital mortality (Table 4).
A subset analysis of risk factors for in-hospitalmortality among
patientswithCR-KPBSI showed that age, chronic kidney disease,
Charlson comorbidity score and ICU onset of CR-KP BSI were
the variables signiﬁcantly associated with mortality (Table 5).
Multivariate analysis adjusted for appropriate antibiotic treat-
ment, combination therapy and removal of the infectious source,
showed Charlson comorbidity score (OR 1.63, 95% CI 1.12–
2.35, p 0.008) and ICUonset of CR-KP infection (OR 31.94, 95%
CI 2.43–419.44, p 0.009) to be the independent risk factors for
in-hospital mortality in this subgroup.
Discussion
Our ﬁndings are consistent with the spread of KPC-3-
producing strains in the hospitals of our region. One-third of
the strains were also resistant to colistin. Combination therapy
was the treatment of choice in c. 60% of CR-KP infections,
with a wide heterogeneity in the antibiotics combination used.
Overall, in-hospital mortality was 25.8%. Underlying condi-
tions, bacteraemia and resistance to colistin, were the
independent risk factors for mortality.
In the last years, K. pneumoniae CC258 producing the KPC-
carbapenemase has been detected as one of the most important
nosocomial pathogens worldwide [1]. We conﬁrmed these
data, indeed 90% of the CR-KP collected in our study were
found to be KPC-producing strains belonging to the CC258
clone. Furthermore, we observed both the carriage of similar
KPC-harbouring plasmids within genetically different strains and
the inter-hospital and intra-hospital spread of ST258 and ST512
strains belonging to the CC258 clone.
In our study, the blaKPC-3 gene has been found on pKpQIL-
related plasmids. These plasmids are characterized by the
TABLE 3. Univariate analysis of risk factors for in-hospital
mortality among 91 patients infected by carbapenem-resis-
tant Klebsiella pneumoniae (CR-KP)
Survivors
(n = 66), n (%)
Non-survivors
(n = 25), n (%) p
Demographic data
Age (years, median, IQR) 68, 45.7–75.2 75, 60–77.5 0.05
Male sex 40 (60.6) 15 (60) 1
Underlying conditions
Immunosuppressiona 27 (40.9) 15 (60) 0.15
Diabetes 23 (34.8) 8 (32) 0.81
Chronic obstructive
pulmonary disease
18 (27.3) 13 (52) 0.04
Chronic kidney disease 15 (22.7) 12 (48) 0.02
Cancer 13 (19.7) 6 (24) 0.77
Chronic liver disease 4 (6.1) 2 (8) 1
Charlson score (median, IQR) 5, 2–8 6, 4–10 0.03
Days of stay before
isolation (median, IQR)
12.5, 7–37 17, 13–25 0.29
Ward of hospitalization
Intensive-care unit 23 (34.8) 21 (84) <0.001
APACHE II score
(median, IQR)b
14, 12–17 18, 12–22 0.12
Medical 34 (51.5) 2 (8) <0.001
Surgical 9 (13.6) 2 (8) 0.51
Mechanism of carbapenem resistance






4 (6.1) 1 (4)
Antibiotic resistance
Imipenem 64 (97) 24 (96) 1
Meropenem 57 (86.4) 24 (96) 0.27
Gentamicin 51 (77.3) 21 (84) 0.57
Colistin 19 (28.8) 13 (52) 0.05
Tigecycline 15 (22.7) 2 (8) 0.14
Fosfomycin 8/14 (57.1) 3/9 (33.3) 0.40
Type of infection
Urinary tract infection 29 (43.9) 0 <0.001
Bloodstream infection (BSI) 18 (27.3) 16 (64) 0.002
Low-risk BSI 10 (15.2) 6 (24) 0.36
High-risk BSI 8 (12.1) 10 (40) 0.006
Lower respiratory
tract infection
8 (12.1) 6 (24) 0.19
Skin and soft tissues infectionc 9 (13.6) 2 (8) 1
Intra-abdominal infection 2 (3) 1 (4) 1
Septic shock 0 15 (60) <0.001
Therapeutic management
Appropriate antibiotic therapy 50 (75.8) 17 (68) 0.59
Antibiotic therapy with
two or more antibiotics
37 (56.1) 17 (68) 0.34
Gentamicin monotherapy 15 (22.7) 1 (4) 0.03
Colistin monotherapy 6 (9.1) 4 (16) 0.45
Colistin plus tigecycline 12 (18.2) 4 (16) 1
Colistin plus fosfomycin 5 (7.6) 0 0.32
Colistin plus gentamicin 3 (4.5) 2 (8) 0.61
Tigecycline plus fosfomycin 4 (6.1) 2 (8) 1
Removal of the
infectious source
19 (28) 7 (28) 1
IQR, interquartile range; ICU, intensive care unit; OmpKs, outer membrane
proteins.
aImmunosuppression includes patients with solid organ transplantation, cortico-
steroid therapy, and human immunodeﬁciency virus infection.
bAPACHE II score at the ICU admission was calculated for the 46 patients
hospitalized in ICU at the time of CR-KP isolation.
cSkin and soft tissues infection includes surgical site infections.
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presence of two replicons, namely FIIk and FIBk, and have been
previously reported and fully sequenced in K. pneumoniae
ST258 from Israel, and in the ﬁrst K. pneumoniae ST258 case to
occur in one of the hospitals of our study in 2010 [25,26]. In
this latter hospital, in which surveillance data were available
before the beginning of our study, we were also able to show a
shift from the ST37 clone, showing ESBL production plus a
porins defect, to the KPC-3 ST512 clone, rapidly becoming the
most prevalent lineage detected among CR-KP [9].
Management of CR-KP infections presents major challenges.
In the literature, clinical data are very limited and consist
mainlyof small case series andbrief reports [27,28]. In a systematic
review [27], combination treatment with aminoglycosides (75%),
polymyxin (73%) and tigecycline (71%) had higher success rates
than monotherapy with carbapenem (40%) or polymyxin (14%).
Indeed, some experts recommend the use of combination
therapy for treatment of severe CR-KP infections [27,28]; this
recommendation was fulﬁlled in about 60% of cases in our study.
The in-hospital mortality rate reported in this study among
patients with CR-KP infection was lower than in previous
reports [15,29,30]. However, as previously showed by other
authors [31], we found that the rate of mortality rose to 47%
among the 34 patients with bacteraemia and BSI was one of the
independent risk factors for in-hospital mortality.
We found an unexpectedly high rate of colistin resistance
among our strains. Maybe the increased use of this drug during
recent years, especially as monotherapy, could be the cause of
this. Unfortunately, data on colistin use in the participating
hospitals, previously and during the study period, were not
available. Furthermore, infectiondue toa colistin-resistantCR-KP
was an independent risk factor formortality. Resistance to colistin
could be simply a marker of the patient’s severity as shown in
infections caused by other resistant microorganisms such as
Pseudomonas aeruginosa and methicillin-resistant Staphylococcus
aureus [14,32]. However, physicians should be aware of such an
occurrence for its implications on treatment and outcome.
Our study has some limitations. The small number of cases
reduces the power of the analysis of risk factors for mortality
as well as the heterogeneity in the infections studied and
antimicrobial treatments.
In conclusion, we showed that the CC258 KPC-producing
strain is becoming prevalent in many hospitals of our region,
mainly due to the inter-hospital and intra-hospital spread of
two major clones. We conﬁrmed the high level of healthcare
exposure among patients colonized or infected by CR-KP. We
found a high rate of resistance to colistin and a high
heterogeneity in the antimicrobial approach. The underlying
conditions, type of CR-KP infection and infection due to a
colistin-resistant strain were independently associated with
worse outcome.
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TABLE 5. Univariate analysis of risk factors for in-hospital
mortality among patients with carbapenem-resistant Klebsi-
ella pneumoniae bloodstream infection
Survivors
(n = 18), n (%)
Non-survivors
(n = 16), n (%) p
Demographic data
Age (years, median, IQR) 54.5, 39–70.2 72, 58.2–77 0.02
Male sex 12 (66.7) 8 (50) 0.48
Underlying conditions
Immunosuppressiona 8 (44.4) 11 (68.8) 0.18
Diabetes 7 (38.9) 7 (43.8) 1
Chronic obstructive
pulmonary disease
4 (22.2) 7 (43.8) 0.27
Chronic kidney disease 2 (11.1) 10 (62.5) 0.003
Cancer 4 (22.2) 3 (18.8) 1
Chronic liver disease 0 2 (12.5) 0.21
Charlson score
(median, IQR)
3.5, 1–6 6, 4–10.7 0.03
Days of stay before
isolation (median, IQR)
12, 6.7–26.7 18, 11.7–31 0.25
Ward of hospitalization
Intensive-care unit 9 (50) 14 (87.5) 0.03
APACHE II score
(median, IQR)b
14, 12–19 20, 13–22 0.22
Medical 5 (27.8) 2 (12.5) 0.40





16 (88.9) 15 (93.8) 1
Enhanced spectrum
b-lactamases + OmpKs
2 (11.1) 1 (6.2)
Colistin resistance 5 (27.8) 7 (43.8) 0.47
Type of bloodstream
infection (BSI)
Low-risk BSI 10 (55.6) 6 (37.5) 0.32
High-risk BSI 8 (44.4) 10 (62.5)
Septic shock 0 11 (68.8) <0.001
Therapeutic management
Appropriate antibiotic therapy 16 (88.9) 12 (75) 0.38
Antibiotic therapy with at
least two antibiotics
14 (77.8) 11 (68.8) 0.70
Removal of the
infectious source
1 (5.6) 2 (12.5) 0.59
IQR, interquartile range; OmpKs, outer membrane proteins.
aImmunosuppression includes patients with solid organ transplantation, cortico-
steroid therapy, and human immunodeﬁciency virus infection.
bAPACHE II score at the ICU admission was calculated for the 23 patients
hospitalized in ICU at the time of CR-KP BSI onset.
TABLE 4. Multivariate analysis of risk factors for in-hospital
mortality in patients with infection due carbapenem-resistant
Klebsiella pneumoniae (CR-KP), adjusted for appropriate
antibiotic treatment, combination therapy and removal of
the infectious source
OR (95% CI) p
Charlson comorbidity score 1.42 (1.15–1.76) 0.001
Hospitalization in intensive-care unit 18.05 (3.90–83.51) <0.001
Bloodstream infection 4.92 (1.35–17.28) 0.01
Infection due to a colistin-resistant strain 4.15 (1.17–14.74) 0.02
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Fig. A1. Number of cases provided by each laboratory/hospital.









patients n = 91,
n (%)
Total n = 97,
n (%)
0.38 0 1 (1.1) 1 (1)
0.50 3 (50) 58 (63.7) 61 (62.9)
1.00 0 1 (1.1) 1 (1)
2.00 0 1 (1.1) 1 (1)
8.00 0 1 (1.1) 1 (1)
16.00 3 (50) 29 (31.9) 32 (33)
Table A2. Relationship between colistin MIC values and
outcome among patients with carbapenem-resistant Klebsi-
ella pneumoniae (CR-KP) infection treated with colistin as
monotherapy or combination therapy
Monotherapy
Survivors Non-survivors
pn = 7, n (%) n = 4, n (%)
Colistin MIC values
0.50 6 (85.7) 2 (50) 0.11
2 1 (14.3) 0
16 0 2 (50)
Combination therapy n = 25, n (%) n = 12, n (%)
Colistin MIC values
0.50 20 (80) 6 (50) 0.05
1 1 (4) 0
16 4 (16) 6 (50)
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